Referenties

French, J. A., Krauss, G. L., Wechsler, R. T., Wang, X. F., DiVentura, B., Brandt, C., . . . Bibbiani, F. (2015). Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: A randomized trial. Neurology,85,1-8. doi: 10.1212/wnl.0000000000001930. 

Colleran, N., T, O. C., & JJ, O. B. (2017). Anti epileptic drug trials for patients with drug resistant idiopathic generalised epilepsy: A meta-analysis. Seizure, 51, 145-156. doi: 10.1016/j.seizure.2017.08.007. 

Giri, V. P., Giri, O. P., Khan, F. A., Kumar, N., Kumar, A., & Haque, A. (2016). Valproic Acid versus Lamotrigine as First-line Monotherapy in Newly Diagnosed Idiopathic Generalized Tonic -Clonic Seizures in Adults - A Randomized Controlled Trial. J Clin Diagn Res, 10(7), FC01-04. doi: 10.7860/jcdr/2016/16911.8121

Hawkins, N., Epstein, D., Drummond, M., Wilby, J., Kainth, A., Chadwick, D., & Sculpher, M. (2005). Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Med Decis Making, 25(5), 493-510. doi: 10.1177/0272989x05280559.

Kasteleijn-Nolst Trenite, D.G., Marescaux, C., Stodieck, S., Edelbroek, P.M. and Oosting, J., 1996. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res, 25(3), pp. 225-30.

Maltoni, S., & Messori, A. (2003). Lifetime cost-utility analysis of patients with refractory epilepsy treated with adjunctive topiramate therapy : cost-effectiveness in refractory epilepsy. Clin Drug Investig, 23(4), 225-232. doi:10.2165/00044011-200323040-00002. 

Marson, A. G., Appleton, R., Baker, G. A., Chadwick, D. W., Doughty, J., Eaton, B., . . . Williamson, P. R. (2007). A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess, 11(37), iii-iv, ix-x, 1-134. doi:10.3310/hta11370.

National Institute for Health and Clinical Excellence (NICE). (2012). The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care, Nice Clinical Guideline 137. London: National Institute for Health and Clinical Excellence.

Noachter, S., Andermann, E., Meyvisch, P., Andermann, F., Gough, W.B. and Schiemann-Delgado, J. (2008). Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology, 70(8), pp. 607-16.

Perucca, E., Gram, L., Avanzini, G. and Dulac, O. (1998). Antiepileptic drugs as a cause of worsening seizures. Epilepsia, 39(1), pp. 5-17.

Remak, E., Hutton, J., Price, M., Peeters, K., & Adriaenssen, I. (2003). A Markov model of treatment of newly diagnosed epilepsy in the UK. An initial assessment of cost-effectiveness of topiramate. Eur J Health Econ, 4(4), 271-278. doi: 10.1007/s10198-003-0176-3.

Remák, E., Hutton, J., Selai, C. E., Trimble, M. R., & Price, M. J. (2004). A cost-utility analysis of adjunctive treatment with newer antiepileptic drugs in the UK. Journal of Medical Economics, 7(1-4), 29-40. doi:10.3111/200407029040.

Sharpe, D.V., Patel, A.D., Abou-Khalil, B. and Fenichel, G.M. (2008). Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure, 17(1), pp. 64-8.

Tjia-Leong ,E., Leong, K., Marson, A.G. (2010) Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. Cochrane Database Syst Rev. Dec 8;(12):CD007783. doi: 10.1002/14651858.CD007783.pub2.

Trinka, E., Marson, A. G., Van Paesschen, W., Kalviainen, R., Marovac, J., Duncan, B., . . . Pohlmann-Eden, B. (2013). KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry, 84(10), 1138-1147. doi: 10.1136/jnnp-2011-300376.